SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- EndoQuest Robotics Announces Completion of Enrollment in the PARADIGM Trial (Business Wire)
- A single blood sample may improve the prediction of colorectal cancer recurrence or metastasis, kaist study finds (EurekAlert)
- At-Home Colorectal Cancer Tests Are Not a One-and-Done Deal (Cancer Health)
- How AI clears the way for colonoscopy screening (American Medical Association)
- Inside Diverticulitis: What Gastroenterologists Need to Know (Medscape)
- Abbott reports diagnostics growth since $21B Exact Sciences buy (Medtech Dive)
- Video Capsule Endoscopy Has Widening Role Beyond Diagnosis of Small-Bowel Bleeding (GI & Endoscopy News)
- How the AGA Incubator is shaping the future of digestive health (AGA)
